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Abstract
Background: Antioxidant supplementation with vitamin E had no effect in the prevention of
cardiovascular diseases (CVD) in three recent large, randomized clinical trials. In order to reassess
critically the role of vitamin E in CVD prevention, it is important to establish whether these results
are related to a lack of antioxidant action.
Methods: We examined the in vivo antioxidant effect of vitamin E (300 mg/day for about three
years) in 144 participants in the Primary Prevention Project (females and males, aged ≥  50 y, with
at least one major CV risk factor, but no history of CVD). Urinary 8-epi-PGF2α  (isoprostane F2α -
III or 15-F2t-isoP), a validated biomarker of lipid peroxidation, was measured by mass spectrometry.
Results: Urinary excretion of 8-epi-PGF2α  [pg/mg creatinine, median (range)] was 141 (67–498)
in treated and 148 (76–561) in untreated subjects (p = 0.10). Taking into account possible
confounding variables, multiple regression analysis confirmed that vitamin E had no significant effect
on this biomarker. Levels of 8-epi-PGF2α  were in the normal range for most subjects, except
smokers and those with uncontrolled blood pressure or hyperglycemia.
Conclusions: Prolonged vitamin E supplementation did not reduce lipid peroxidation in subjects
with major cardiovascular risk factors. The observation that the rate of lipid peroxidation was near
normal in a large proportion of subjects may help explain why vitamin E was not effective as an
antioxidant in the PPP study and was ineffective for CVD prevention in large scale trials.
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Background
The "oxidative hypothesis" of atherosclerosis proposes
that oxidative modification of lipids in low-density lipo-
proteins (LDL) contributes to atherogenesis [1,2]. Anti-
oxidants that are effective against lipid peroxidation
should therefore reduce atherosclerosis and hence afford
protection from cardiovascular diseases (CVD)[1]. In con-
trast to a) epidemiological evidence that antioxidants tak-
en with the diet or as supplements reduce cardiovascular
(CV) risk [3], and b) experimental data supporting its
anti-atherogenic properties [4], vitamin E failed to show
any beneficial effect in recent large intervention studies
[5]. In two large-scale trials, long-term supplementation
with vitamin E (300–400 lU/day) failed to reduce cardio-
vascular events in post-myocardial infarction patients
(GISSI-Prevenzione [6]) and in subjects at high CV risk
(HOPE [7]). In the trial conducted by our group (Primary
Prevention Project, PPP [8]), vitamin E (300 mg/day) tak-
en over three years also showed no effect on the incidence
of cardiovascular events in individuals with one or more
major risk factors (see Methods). Therefore, the question
whether vitamin E had an effective in vivo antioxidant ac-
tion in the populations under study in these trials is under
debate [9–12].
When these studies were designed, the antioxidant effica-
cy of vitamin E in humans had not been demonstrated in
vivo because of the lack of reliable methods [13]. Measure-
ment of urinary or circulating F2-isoprostanes (iPF2 or F2-
isoP) is now accepted as a reliable tool for evaluating the
rate of lipid peroxidation in vivo[9,14–16]. Using urinary
excretion of 8-epi-PGF2α  (also termed iPF2α -III or 15-F2t-
isoP) as a biomarker, it has been shown that short-term
administration of vitamin E (600 mg/day for 14 days) re-
duced in vivo lipid peroxidation in some clinical settings
where oxidative stress is abnormally high, e.g., diabetes
mellitus (-37%), hypercholesterolemia (-58%) and cystic
fibrosis (-42%) [17–19]. In contrast, vitamin E had no
antioxidant activity in conditions where lipid peroxida-
tion was normal [20]. No data are available on the anti-
oxidant effect of longer-term supplementation with
vitamin E in subjects at moderate/high cardiovascular
risk.
Using a highly selective and validated mass spectrometric
assay for 8-epi-PGF2α [21], we measured in vivo lipid per-
oxidation in PPP trial participants who had taken vitamin
E daily for about three years vs those who did not take vi-
tamin E.
Methods
PPP is a large, randomized, controlled 2 ×  2 factorial trial
on primary prevention of CVD [8]. It was designed to test
the efficacy of long-term administration of vitamin E (syn-
thetic  α -tocopherol, 300 mg/day) and/or aspirin (100
mg/day) in preventing cardiovascular events in subjects of
both sexes aged ≥  50 years, with at least one of the follow-
ing cardiovascular risk factors: old age (≥  65 yr); hyperten-
sion (systolic blood pressure ≥  160 mm Hg or diastolic
blood pressure ≥  95 mm Hg on at least three separate oc-
casions); hypercholesterolemia (≥  250 mg/dL on at least
two separate occasions); diabetes mellitus (≥  140 mg/dL
fasting venous plasma glucose, on at least two separate oc-
casions); chronic drug treatment for any of the three latter
conditions; obesity (body mass index ≥  30 kg/m2); and
premature myocardial infarction before 55 years of age in
at least one parent or sibling. Patients with a history of car-
diovascular events or diseases were not included. Table 1
shows the frequency of these CV risk factors in our sam-
ple.
Overnight urine was obtained from subjects consecutively
presenting at five participating centers for a scheduled fol-
low-up visit after at least one year of randomized treat-
ment. With a sample size of 70 individuals per arm, the
study had a 90% power (1-β ) to detect, with α  = 0.05, a
difference of at least 25% in urinary 8-epi-PGF2α  between
treated and untreated individuals. Two groups of 72 sub-
jects treated or not treated with vitamin E were studied.
Clinical and biochemical variables were reassessed yearly
and on the occasion of urine collection.
Urinary 8-epi-PGF2α  was selectively measured as we have
described previously [21] using immunoaffinity chroma-
tography for selective extraction/purification and a stable
isotope dilution assay with gas chromatography-negative
ion chemical ionization mass spectrometry for quantita-
tion, with 2H4-8-epi-PGF2α  as the internal standard. Uri-
nary excretion of 8-epi-PGF2α  was expressed as pg/mg
creatinine. Creatinine was measured highly selectively by
stable-isotope dilution HPLC-electrospray-tandem mass
spectrometry, using 2H3-creatinine as the internal stand-
Table 1: Major cardiovascular risk factors in the 144 subjects.
RISK FACTOR* n(%)
Old age ≥  65 y 38 (26)
Male sex 63 (44)
Smoking 24 (17)
Hypertension 136 (94)
Diabetes 12(8)
Hypercholesterolemia 43 (30)
Obesity 32 (22)
Family history of premature myocardial 
infraction
17 (12)
*See Methods for definitionCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/5
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ard. Urine was stored at -20°C until analyzed. Analyses
were done on blind-coded samples.
Means were compared by the non-parametric Mann-
Whitney U test to avoid assumptions about the distribu-
tion of the variables. Levels of 8-epi-PGF2α  were expressed
as median (range) values. Multiple regression analysis was
used to 1) evaluate the effect of vitamin E on urinary ex-
cretion of 8-epi-PGF2α , taking into account the following
potential confounding variables (age, sex, aspirin treat-
ment, smoking, systolic and diastolic blood pressure,
blood glucose, blood cholesterol and obesity), and 2) as-
sess whether any of these variables was independently as-
sociated with lipid peroxidation. Linear correlation
analysis was also used. Probability values of p ≤  0.05 (two
tails) were considered to be statistically significant.
Results
1. Antioxidant Effect of Vitamin E
In vivo lipid peroxidation was not reduced significantly by
vitamin E (Figure 1), as indicated by the similar urinary
excretion of 8-epi-PGF2α  in the supplemented group and
in the controls [141 (67–498) vs 148 (76–561) pg/mg cre-
atinine, p = 0.10]. These subjects had mean ± SD follow-
up durations of 2.8 ± 1.0 and 2.7 ± 1.1 years, respectively.
Baseline characteristics were well balanced across the two
study groups, except for a slight difference in blood levels
of glucose and cholesterol (Table 2). For this reason, we
excluded with reasonable confidence a potential bias due
to different baseline levels of urinary 8-epi-PGF2α . Multi-
ple regression analysis, which takes into account possible
confounding variables at the time of urine collection (age,
sex, smoking, blood glucose, blood cholesterol, systolic
and diastolic blood pressure, body mass index, aspirin
treatment), confirmed that vitamin E had no significant
overall effect on urinary 8-epi-PGF2α  (β  = -0.14, p = 0.12,
Table 3).
Smoking was the only strong determinant of lipid peroxi-
dation in the overall sample (Table 3, discussed below).
Since it is known that vitamin E does not reduce excessive
lipid peroxidation in smokers [22,23], we investigated
whether the presence of smokers in our sample might
mask an antioxidant effect of vitamin E in the nonsmok-
ers (n = 120; 63 untreated, 57 treated with vitamin E). The
Table 2: Baseline characteristics of the two study groups
VITAMIN E (n = 72) NO VITAMIN E (n = 72)
Age (y) 59 ± 6 61 ± 7
Sex (M/F) 32/40 31/41
Body mass index (kg/m2)2 7   ± 4 27 ± 4
Smokers (yes/no) 15/57 9/63
Systolic blood pressure (mm Hg) 146 ± 16 145 ± 15
Diastolic blood pressure (mm Hg) 88 ± 8 87 ± 7
Blood glucose (mg/dL) 91 ± 32 103 ± 35**
Total blood cholesterol (mg/dL) 243 ± 47 225 ± 45*
Aspirin treatment (yes/no) 36/36 34/38
Values are expressed as mean ± SD or number. *p < 0.05, **p < 0.01
Figure 1
Urinary excretion of 8-epi-PGF2α  in PPP participants supple-
mented or not with vitamin E. Smokers are indicated by filled
circles. The horizontal lines represent the median.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/5
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levels of 8-epi-PGF2α  in nonsmokers, however, were not
significantly reduced by prolonged vitamin E supplemen-
tation [122 (67–326) vs 146 (76–316), p = 0.09)]. Multi-
variate analysis confirmed that vitamin E did not reduce
lipid peroxidation in this sample (β  = -0.10, p = 0.32, Ta-
ble 3).
2. Lipid Peroxidation in Subjects at CV Risk
Since vitamin E has thus far proved effective as an in vivo
antioxidant in humans when lipid peroxidation is exces-
sive [17–19,24], but not when it is normal [20], we ad-
dressed the question whether in subjects eligible for
primary prevention of CVD, lipid peroxidation was in-
creased enough to decrease appreciably with vitamin E. As
a whole, this sample of patients with at least one CVD risk
factor did not have an abnormal rate of lipid peroxida-
tion. The levels of urinary 8-epi-PGF2α  in untreated non-
smokers [146 (76–316) pg/mg creatinine] were similar to
those of controls in other studies where this biomarker
was selectively measured by mass spectrometry [20,22].
They were also similar to those we found in healthy non-
smoking volunteers [139 (71–256) pg/mg creatinine;
mean ± SD age, 37 ± 11y; n = 20, unpublished data].
To better characterize the level of CV risk in our sample,
we calculated a global CV risk score for each subject. We
used Framingham's multiple-risk-factor assessment equa-
tion, a function assessing the risk of developing coronary
heart disease on the basis of the presence and the level of
major CV risk factors [25]. As shown in Figure 2, urinary
8-epi-PGF2α  did not correlate with risk level in untreated
or treated subjects.
We therefore analyzed more closely factors possibly asso-
ciated with lipid peroxidation in our sample, which is
rather heterogeneous but is fairly representative of a pop-
ulation with major risk factors for cardiovascular diseases.
3. Factors Associated with Lipid Peroxidation in Subjects at 
CV Risk
Smoking
Multiple regression analysis of the whole group of 144
subjects showed cigarette smoking was the only strong de-
terminant of excessive lipid peroxidation (β  = 0.46; p <
0.0001, Table 3). Urinary excretion of 8-epi-PGF2α  was
higher in smokers (n = 24; 14 ± 6 cigarettes daily) than
nonsmokers (n = 120) [185 (91–561) vs 138 (67–326)
pg/mg creatinine; p = 0.003]. Vitamin E did not signifi-
cantly reduce levels of 8-epi-PGF2α  in smoking PPP partic-
ipants [179 (91–498) vs 199 (138–561) pg/mg creatinine;
p = 0.44; n = 15 and 9, respectively].
Other factors
The presence of smoking, a strong determinant of lipid
peroxidation, very likely hampered the detection of other
clinically important variables possibly associated with uri-
nary 8-epi-PGF2α  in our initial sample. We therefore in-
vestigated the relationship between these variables and 8-
epi-PGF2α  levels in the 120 nonsmokers.
Systolic blood pressure
Lipid peroxidation appeared to be related to systolic
blood pressure in nonsmokers (β  = 0.26; p = 0.02, Table
3). To confirm this in a less heterogeneous sample, we an-
alyzed a subgroup of subjects who had hypertension as
the only risk factor (n = 45). All except one were under an-
tihypertensive treatment, with mean ± SD systolic and di-
astolic blood pressure 145 ± 16 (range 107–187) and 87
± 8 (range 64–105) mm Hg, respectively. In this sub-
group, the correlation between systolic blood pressure
Table 3: Multiple regression analysis: variables associated with urinary excretion of 8-epi-PGF2α
all subjects (n = 144) nonsmokers (n = 120)
VARIABLE β p β p
Smoking 0.46 <0.0001 – –
Vitamin E treatment -0.14 0.12 -0.10 0.32
Systolic blood pressure (mmHg) 0.13 0.19 0.26 0.02
Obesity 0.12 0.21 0.15 0.15
Sex (M) 0.11 0.22 0.13 0.21
Aspirin treatment -0.10 0.24 -0.07 0.45
Blood glucose (mg/dL) 0.09 0.35 0.17 0.11
Diastolic blood pressure (mmHg) -0.05 0.63 -0.07 0.50
Age (y) 0.04 0.67 0.09 0.38
Blood cholesterol (mg/dL) 0.03 0.74 0.11 0.30Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/5
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and urinary excretion of 8-epi-PGF2α  was highly signifi-
cant (r = 0.50, p = 0.0005. Figure 3), and subjects with
systolic blood pressure ≥  140 mm Hg had higher excretion
of 8-epi-PGF2α  than those with <140 mm Hg [151 (140–
187) vs 127 (107–139) pg/mg creatinine, n = 27 and 18,
respectively, p = 0.004]. Vitamin E did not significantly af-
fect 8-epi-PGF2α  excretion [109 (67–240) vs 138 (76–
266) pg/mg creatinine in 21 treated and 24 untreated hy-
pertensive subjects; p = 0.19].
Hyperglycemia
In nonsmoking participants, blood glucose measured at
the time of urine collection (mean ± SD: 108 ± 24 mg/dL,
n = 94) did not appear to be related to lipid peroxidation,
based on multiple regression analysis (β  = 0.17, p = 0.11.
Table 3). However, subjects with blood glucose ≥  140 mg/
dL had higher excretion of 8-epi-PGF2α  than those with
<140 mg/dL [180 (121–326) vs 140 (70–266), n = 10 and
84, respectively, p = 0.009)], likely because only high
blood glucose levels may be associated with excessive lip-
id peroxidation.
Other factors
In nonsmoking PPP participants, blood cholesterol at the
time of urine collection (mean ± SD: 231 ± 40 mg/dL,
range 144–351) was not significantly associated with lipid
peroxidation (Table 3). Aspirin administration (n = 72)
did not affect urinary excretion of 8-epi-PGF2α  (Table 3),
as already reported [14,26]. We found no evidence (Table
3) of increased lipid peroxidation in relation to age, sex or
obesity.
Discussion
Long-term supplementation with vitamin E-at a dose
largely exceeding that of a vitamin E-rich diet (300 mg/
day)-did not substantially reduce lipid peroxidation in
people with one or more major cardiovascular risk factors.
This may help explain why vitamin E was not effective for
CVD prevention in the PPP study. As opposed to other
studies showing an antioxidant effect of vitamin E in
small, uncontrolled subgroups of patients, our observa-
tions were obtained in a sample of subjects that more re-
alistically represent a population with cardiovascular risk
factors. In fact, as usually occurs in clinical practice, most
candidates for cardiovascular prevention are treated-al-
though not necessarily controlled-for their modifiable
risk factors. The lack of antioxidant effect in our sample
may be explained by the rather surprising finding that lip-
id peroxidation was normal in a large proportion of these
subjects.
Figure 2
Correlation between global CV risk level and urinary excre-
tion of 8-epi-PGF2α  in PPP participants without (upper panel)
or with (lower panel) vitamin E supplementation. Risk levels,
calculated according to Framingham's multiple-risk-factor
assessment equation, represent coronary heart disease
(CHD) individual risk over the next ten years [25].
Figure 3
Correlation between systolic blood pressure and urinary
excretion of 8-epi-PGF2α  in 45 PPP participants with hyper-
tension as the only risk factor.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/5
Page 6 of 7
(page number not for citation purposes)
We investigated whether oxidative stress was increased in
high-risk subjects, given that this category could, in prin-
ciple, be more sensitive to antioxidant therapy. However,
we found no evidence of a correlation between CV risk
score and urinary excretion of 8-epi-PGF2α  in untreated
subjects, suggesting that lipid peroxidation was not asso-
ciated with their global CV risk. Although, on average, li-
pid peroxidation was normal in our population, it was
clearly increased in relation to extreme conditions report-
edly associated with oxidative stress. Lipid peroxidation
was, in fact, significantly higher in smokers, in agreement
with consistent evidence of elevated oxidative stress in cig-
arette smokers, mostly obtained using 8-epi-PGF2α  and/
or other F2-isoprostanes as biomarkers [21,22,27]. We
also confirmed previous observations that excessive lipid
peroxidation in smokers cannot be reduced by vitamin E
[22,23].
A secondary, but original finding of this study is the direct
relationship between urinary excretion of an F2-isopros-
tane and systolic blood pressure in treated hypertensive
patients with different degrees of blood pressure control.
Whether this relationship also exists in untreated hyper-
tensive patients should be investigated. An association be-
tween oxidative stress and arterial hypertension has been
suggested by several clinical and experimental studies
[28–32]. The hypothesis that free radical-mediated mech-
anisms may play a role in the pathophysiology of hyper-
tension has recently gained support from observations
that antioxidants lower blood pressure in hypertensive pa-
tients [30,33–36]. However, vitamin E in particular does
not seem effective [37], possibly because it was not anti-
oxidant in these circumstances.
As to other factors reportedly related to in vivo lipid perox-
idation, our findings agree with previous evidence. In par-
ticular, we confirmed that enhanced urinary excretion of
8-epi-PGF2α  is associated with impaired glycemic control
in diabetic patients [17]. We did not find a correlation be-
tween urinary excretion of 8-epi-PGF2α  and blood choles-
terol, which, on average, was slightly elevated in our
sample. Such a correlation was, in fact, found in subjects
with homozygote familial hypercholesterolemia and in
subjects with very high blood cholesterol, but not in those
with normal cholesterol levels [24].
Conclusions
Prolonged supplementation with 300 lU/day vitamin E
did not reduce lipid peroxidation in subjects with one or
more major cardiovascular risk factors. On average, how-
ever, lipid peroxidation was near-normal in this popula-
tion. These data may help explain the overall lack of
benefit of vitamin E in recent cardiovascular prevention
trials [6–8]. They also suggest the need to reassess whether
lipid peroxidation is indeed an epidemiologically relevant
determinant of cardiovascular diseases and, consequently,
to reconsider the utility of antioxidants as a general pre-
ventive measure.
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